BEDMINSTER, NJ and DUBLIN, IRELAND–(Marketwired – December 02, 2015) – Amarin Corporation plc (AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin’s President and Chief Executive Officer, is scheduled to present a general company update at the Oppenheimer & Co. Inc. 26th Annual Healthcare Conference in New York City on Wednesday, December 9, 2015, at 9:10 a.m. ET.
A live audio webcast of the presentation will be available at:
Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin’s product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Amarin’s clinical program includes commitment to an ongoing outcomes study. Vascepa® (icosapent ethyl), Amarin’s first FDA approved product, is a highly-pure, EPA-only, omega-3 fatty acid product available by prescription. For more information about Vascepa visit www.vascepa.com. For more information about Amarin visit www.amarincorp.com.
Kathryn McNeil or Michael Farrell
Investor Relations and Corporate Communications
Amarin Corporation plc
In U.S.: +1 (908) 719-1315
In U.S.: +1 (646) 378-2954
In U.S.: +1 (212) 508-9651